This article we will find out what ATMPs are and what distinguishes them from traditional drugs, as well as what ATMP applications in FemTech health are, focusing on the prenatal and perinatal stages of life.
We will also provide an overview of the target genetic disorders diseases currently identified and the different delivery platforms used for in-utero gene therapy.
The acronym ATMPs stands for Advanced Therapy Medicinal Products.
This category of medicinal products includes products that differ from more "traditional" drugs, those which are based on DNA or RNA, cells and tissues, rather than on molecules produced by chemical synthesis.
Advanced therapies represent a very 'young' sector; these therapies are experiencing robust development and offer new opportunities for diagnosis, prevention and/or treatment of serious pathologies that have limited or no therapeutic options, such as genetic disorders, chronic diseases and tumors.